GenBioPro

In 2019 GenBioPro obtained Food and Drug Administration (FDA) authorization to sell a generic version of mifepristone (before that, Danco Laboratories was the only company that distributed it in the United States).^[1][2] Despite the FDA saying that it tries to approve generic drug applications in 10 months, this application was approved after 10 years (the company applied in 2009).^[3]

In 2023, GenBioPro sued the FDA to obtain a legal judgement confirming that mifepristone could continue to be sold, in spite of anti-abortion laws passed in some states.^[4][5]

• Birth control movement in the United States
• Exelgyn
• Medical abortion